{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:56:19Z","timestamp":1787169379594,"version":"build-2736575974"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril\/Valsartan therapy. As HFpEF patients with pulmonary hypertension display a specifically high mortality and morbidity, we evaluated the effect of Sacubitril\/Valsartan in this subgroup of HFpEF patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    In this retrospective case-series of 18 patients with HFpEF and pulmonary hypertension, right heart catheterisation (RHC) for determination of invasive pulmonary pressure were performed at baseline (pre-Sacubitril\/Valsartan) and 99 (71\u2013156) days after transition from angiotensin-converting enzyme inhibitors and angiotensin receptor blockers to Sacubitril\/Valsartan (post-Sacubitril\/Valsartan). Results are given as median and interquartile range.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    After conversion to Sacubitril\/Valsartan, RHC showed significantly reduced pulmonary artery pressure (PAP) and mean pulmonary capillary wedge pressure (PCWP) compared to pre-Sacubitril\/Valsartan [PAP systolic\/diastolic\/mean 44 (38\u201355)\/15 (11\u201320)\/27 (23\u201333) mm Hg vs. 51 (41\u201382)\/22 (13\u201329)\/33 (28\u201352) mm Hg,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.05 and\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.01, respectively; PCWP 16 (12\u201320) mm Hg vs. 22 (15\u201327) mm Hg,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.05]. Median Sacubitril\/Valsartan dosage was 24\/26 mg BID (24\/26 BID\u221249\/51 mg BID). Clinically, New York Heart Association functional class improved in 12 of the 18 patients (\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.01) after conversion to Sacubitril\/Valsartan. Echocardiographic parameters of left ventricular function and cardiovascular co-medication did not differ markedly between pre- and post-Sacubitril\/Valsartan.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Sacubitril\/Valsartan therapy is associated with an improvement of pulmonary hypertension in HFpEF patients.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2021.734697","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:15:47Z","timestamp":1638389747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Reduction of Pulmonary Hypertension After Transition to Sacubitril\/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction"],"prefix":"10.3389","volume":"8","author":[{"given":"Christof","family":"Burgdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Brockm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrieke","family":"Strampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Januszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern Andrew","family":"Remppis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"118877","DOI":"10.1016\/j.lfs.2020.118877","article-title":"Sacubitril\/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism","volume":"266","author":"Liu","year":"2020","journal-title":"Life Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e005819","DOI":"10.1161\/CIRCHEARTFAILURE.119.005819","article-title":"Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril\/valsartan","volume":"12","author":"Clements","year":"2019","journal-title":"Circ Heart Fail."},{"key":"B6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ehf2.12610","article-title":"Sacubitril\/valsartan in patients listed for heart transplantation: effect on physical frailty","volume":"7","author":"Cacciatore","year":"2020","journal-title":"ESC Heart Fail."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ehf2.13225","article-title":"Acute pulmonary pressure change after transition to sacubitril\/valsartan in patients with heart failure reduced ejection fraction","volume":"8","author":"Tran","year":"2021","journal-title":"ESC Heart Fail."},{"key":"B8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cardfail.2014.05.003","article-title":"Outcomes in world health organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension","volume":"20","author":"Salamon","year":"2014","journal-title":"J Card Fail."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"353S","DOI":"10.1042\/CS103S353S","article-title":"Role of endothelin-converting enzyme, chymase and neutral endopeptidase in the processing of big ET-1, ET-1(1-21) and ET-1(1-31) in the trachea of allergic mice","volume":"103","author":"De Campo","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/cbic.201600244","article-title":"The metalloprotease neprilysin degrades and inactivates apelin peptides","volume":"17","author":"McKinnie","year":"2016","journal-title":"Chembiochem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"823193","DOI":"10.1155\/2012\/823193","article-title":"Targeting the ACE2 and apelin pathways are novel therapies for heart failure: opportunities and challenges","volume":"2012","author":"Kazemi-Bajestani","year":"2012","journal-title":"Cardiol Res Pract."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.734697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:15:48Z","timestamp":1638389748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.734697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":13,"alternative-id":["10.3389\/fcvm.2021.734697"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.734697","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"article-number":"734697"}}